Circulating somatostatin acts on the islets of Langerhans by way of a somatostatin-poor compartment.
Somatostatin perfused in canine pancreases at 10 to 20 picograms per milliliter or 10 to 20 percent of the pancreatic vein somatostatin concentration inhibited insulin and glucagon secretion. This suggests that the high local concentration of endogenous somatostatin is not in contact with somatostatin receptors of the islets. The integrity of this separation may determine the sensitivity of islet cells to circulating somatostatin.
D000818:Animals; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005934:Glucagon / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007365:Intercellular Junctions / Q000502:physiology; D007515:Islets of Langerhans / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000502:physiology; D017481:Receptors, Somatostatin; D013004:Somatostatin / Q000097:blood* / Q000378:metabolism
D007328:Insulin; D011956:Receptors, Cell Surface; D017481:Receptors, Somatostatin; D013004:Somatostatin; D005934:Glucagon